Efgartigimod alfa (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Efgartigimod alfa" in English language version.

refsWebsite

Global rank English rank

11web.archive.org

1^st place

6fda.gov

447^th place

338^th place

3europa.eu

68^th place

117^th place

2hpfb-dgpsa.ca

low place

2argenx.com

low place

2statnews.com

8,771^st place

5,253^rd place

1nih.gov

4^th place

1businesswire.com

615^th place

407^th place

1clinicaltrials.gov

5,225^th place

4,062^nd place

1pharmaceutical-technology.com

low place

1drugbank.com

low place

1handle.net

102^nd place

76^th place

argenx.com

"Argenx Announces U.S. Food and Drug Administration Approval of Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Generalized Myasthenia Gravis". Argenx (Press release). 20 June 2023. Retrieved 24 June 2023.
"Argenx Announces U.S. Food and Drug Administration (FDA) Approval of Vyvgart (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis" (Press release). Argenx. 17 December 2021. Archived from the original on 20 December 2021. Retrieved 21 December 2021.

businesswire.com

"Argenx Announces U.S. Food and Drug Administration (FDA) Approval of Vyvgart (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis" (Press release). Argenx. 17 December 2021. Archived from the original on 19 December 2021. Retrieved 21 December 2021 – via Business Wire.

clinicaltrials.gov

argenx (3 August 2023). A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Report). clinicaltrials.gov.

drugbank.com

go.drugbank.com

"Efgartigimod alfa". Drugbank. Archived from the original on 5 February 2022. Retrieved 19 July 2022.

europa.eu

ema.europa.eu

"Vyvgart EPAR". European Medicines Agency (EMA). 20 June 2022. Archived from the original on 28 September 2022. Retrieved 27 September 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Vyvgart: Pending EC decision". European Medicines Agency (EMA). 24 June 2022. Archived from the original on 26 June 2022. Retrieved 26 June 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

ec.europa.eu

"Vyvgart Product information". Union Register of medicinal products. 12 December 2022. Retrieved 3 March 2023.

fda.gov

"FDA Approves New Treatment for Myasthenia Gravis". U.S. Food and Drug Administration (FDA) (Press release). 17 December 2021. Archived from the original on 20 December 2021. Retrieved 21 December 2021. This article incorporates text from this source, which is in the public domain.
"Drug Trials Snapshot: Vyvgart". U.S. Food and Drug Administration (FDA). 23 May 2023. Retrieved 27 May 2023. This article incorporates text from this source, which is in the public domain.
Advancing Health Through Innovation: New Drug Therapy Approvals 2021 (PDF). U.S. Food and Drug Administration (FDA) (Report). 13 May 2022. Archived from the original on 6 December 2022. Retrieved 22 January 2023. This article incorporates text from this source, which is in the public domain.

accessdata.fda.gov

"Efgartigimod alfa Orphan Drug Designations and Approvals". U.S. Food and Drug Administration (FDA). 2 January 2019. Archived from the original on 22 December 2021. Retrieved 21 December 2021.
"Efgartigimod alfa Orphan Drug Designations and Approvals". U.S. Food and Drug Administration (FDA). 20 September 2017. Archived from the original on 22 December 2021. Retrieved 21 December 2021.
"Efgartigimod alfa Orphan Drug Designations and Approvals". U.S. Food and Drug Administration (FDA). 11 August 2021. Archived from the original on 8 November 2021. Retrieved 21 December 2021.

handle.net

hdl.handle.net

World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 78". WHO Drug Information. 31 (3). hdl:10665/330961.

hpfb-dgpsa.ca

dhpp.hpfb-dgpsa.ca

"Details for: Vyvgart". Health Canada. 6 November 2023. Retrieved 3 March 2024.
"Summary Basis of Decision (SBD) for Vyvgart". Drug and Health Products Portal. 1 September 2012. Retrieved 9 May 2024.

nih.gov

dailymed.nlm.nih.gov

"Vyvgart- efgartigimod alfa injection". DailyMed. Archived from the original on 25 December 2021. Retrieved 24 December 2021.

pharmaceutical-technology.com

kgi-admin (25 December 2023). "Efgartigimod alfa by Argenx for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Likelihood of Approval". Pharmaceutical Technology. Retrieved 9 March 2024.

statnews.com

Feuerstein A (17 July 2023). "Argenx antibody drug significantly slows progression of nerve disorder that robs patients of muscle strength". STAT. Retrieved 9 March 2024.
"STATUS List - Tim Van Hauwermeiren". STAT. Retrieved 9 March 2024.

web.archive.org

"Vyvgart- efgartigimod alfa injection". DailyMed. Archived from the original on 25 December 2021. Retrieved 24 December 2021.
"FDA Approves New Treatment for Myasthenia Gravis". U.S. Food and Drug Administration (FDA) (Press release). 17 December 2021. Archived from the original on 20 December 2021. Retrieved 21 December 2021. This article incorporates text from this source, which is in the public domain.
"Vyvgart EPAR". European Medicines Agency (EMA). 20 June 2022. Archived from the original on 28 September 2022. Retrieved 27 September 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Argenx Announces U.S. Food and Drug Administration (FDA) Approval of Vyvgart (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis" (Press release). Argenx. 17 December 2021. Archived from the original on 20 December 2021. Retrieved 21 December 2021.
"Argenx Announces U.S. Food and Drug Administration (FDA) Approval of Vyvgart (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis" (Press release). Argenx. 17 December 2021. Archived from the original on 19 December 2021. Retrieved 21 December 2021 – via Business Wire.
Advancing Health Through Innovation: New Drug Therapy Approvals 2021 (PDF). U.S. Food and Drug Administration (FDA) (Report). 13 May 2022. Archived from the original on 6 December 2022. Retrieved 22 January 2023. This article incorporates text from this source, which is in the public domain.
"Efgartigimod alfa". Drugbank. Archived from the original on 5 February 2022. Retrieved 19 July 2022.
"Efgartigimod alfa Orphan Drug Designations and Approvals". U.S. Food and Drug Administration (FDA). 2 January 2019. Archived from the original on 22 December 2021. Retrieved 21 December 2021.
"Efgartigimod alfa Orphan Drug Designations and Approvals". U.S. Food and Drug Administration (FDA). 20 September 2017. Archived from the original on 22 December 2021. Retrieved 21 December 2021.
"Efgartigimod alfa Orphan Drug Designations and Approvals". U.S. Food and Drug Administration (FDA). 11 August 2021. Archived from the original on 8 November 2021. Retrieved 21 December 2021.
"Vyvgart: Pending EC decision". European Medicines Agency (EMA). 24 June 2022. Archived from the original on 26 June 2022. Retrieved 26 June 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.